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Chimeric antigen receptors are synthetic molecules
designed to re-direct T cells to specific surface antigens;
CAR-modified T cells can mediate long-term durable
remissions in B cell malignancies, but expanding this
platform to solid tumors requires the discovery of novel
surface targets with limited expression. The variant III
mutation of the epidermal growth factor receptor (EGFR
variant III) is the most common variant of the EGF
receptor observed in human tumors, and results from an
in-frame deletion of a portion of the extracellular domain.
In glioblastoma, the EGFRvIII mutation is oncogenic,
portends a poor prognosis, and is thought to be enriched
in glioblastoma stem cells. However, because the neoepi-
tope of EGFR variant III is based on a small peptide
sequence, an antibody or single-chain variable fragment
(scFv) directed to this epitope must be rigorously tested
to confirm lack of cross-reactivity to the ubiquitously
expressed normal EGFR. Having selected a candidate
murine scFv directed to EGFRvIII and a vector backbone
encoding a second generation CAR, we generated a panel
of humanized scFv’s and tested their specificity and func-
tion as soluble proteins and in the form of CAR-
transduced T cells. The lead candidate scFv was tested
in vitro for its ability to direct CAR-transduced T cells
to kill antigen-bearing targets effectively, and proliferate
and secrete cytokines specifically in response to antigen.
We further evaluated the specificity of the lead candidate
CAR by comparing it to a cetuximab-based CAR which
does not discriminate between EGFR and EGFR variant
III; the two CARs, along with negative controls, were
tested in vitro against primary cells derived from a panel
of normal tissues, and in vivo in immunodeficient mice
grafted with normal human skin, which naturally
expresses EGFR. CAR-T cells were also able to control
tumor growth in xenogeneic subcutaneous and orthoto-
pic models of human EGFR variant III+ glioblastoma.
We have designed a Phase I clinical study of CAR T cells
transduced with humanized scFv directed to EGFR var-
iant III in patients with glioblastoma.
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